(Q36642130)

15 August 2017

1 reference

title

Ovarian cancer: a focus on management of recurrent disease (English)

1 reference

15 August 2017

1 reference

Thomas J Herzog

1

1 reference

15 August 2017

Bhavana Pothuri

series ordinal

2

1 reference

15 August 2017

publication date

1 November 2006

1 reference

Nature Clinical Practice Oncology

15 August 2017

published in

1 reference

15 August 2017

volume

3

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

604-611

1 reference

15 August 2017

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Second-line treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Recurrent ovarian cancer: how important is it to treat to disease progression?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Liposomal anthracycline treatment for ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Topotecan in Platinum- and Paclitaxel-Resistant Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Clinical update: novel targets in gynecologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

TLK-286: a novel glutathione S-transferase-activated prodrug

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

The combination of yondelis and cisplatin is synergistic against human tumor xenografts

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Evaluation of treatment and survival after positive second-look laparotomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Integrating radiation therapy into the management of ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Intraoperative radiation therapy in recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0637

7 January 2021

Identifiers

DOI

10.1038/NCPONC0637

1 reference

release_6oud745wmnh4fkeqltcuzaxi3i

15 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6oud745wmnh4fkeqltcuzaxi3i

24 November 2022

mapped directly with Wikidata item

1 reference